3-V Biosciences Appoints Edward M. Connor, Jr., MD, Chief Medical Officer
6/3/2010 9:02:39 AM
MENLO PARK, Calif., June 3 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of Edward M. Connor, Jr., MD, as Chief Medical Officer.
"Ed Connor is among the most experienced respiratory infectious disease drug developers in the world, having led the development of RespiGam and Synagis® for respiratory syncytial virus and FluMist® for influenza," said David M. Mott, 3-V's Executive Chairman. "He has further extensive experience in infectious disease, immunology and oncology from his role as Executive Vice President and Chief Medical Officer at MedImmune, where he spent 14 years until 2008 following MedImmune's sale to AstraZeneca."
At 3-V, Dr. Connor will be responsible for directing all medical activities and will work with the senior management group to select targets, develop target product profiles, create and execute product development plans, and identify and work with key thought leaders. "Ed is a perfect fit for 3-V given our initial focus in respiratory infectious diseases. His knowledge of clinical trial design and execution, and his tremendous regulatory experience, will be immensely valuable as we move our initial compounds forward. In the future, as we expand 3-V's focus in infectious diseases, Ed's additional experience across HIV, CMV, HPV and other pathogens will be helpful to determine where to best apply our host-directed approach to infectious disease," added Mott.
Dr. Connor is currently Director, Office of Investigational Therapeutics, Children's National Medical Center and a Professor of Pediatrics at the George Washington School of Medicine and Health Sciences. He will continue in those roles while serving as 3-V's Chief Medical Officer. Previously, Dr. Connor was Executive Vice President and Chief Medical Officer at MedImmune, Inc., where he served in roles of increasing responsibility over his 14-year tenure. Prior to joining MedImmune, Dr. Connor served as the Chief of Pediatric Infectious Diseases, Director of Pediatric HIV Research, and Principal Investigator of the National Institutes of Health-funded pediatric AIDS clinical trials unit at the University of Medicine and Dentistry of New Jersey. During that time, Dr. Connor also served at a national level as Chairman of the Pediatric AIDS Clinical Trials Group and the Perinatal HIV Research Committee. Dr. Connor holds a bachelor's degree in biology from Villanova University in Villanova, PA, and a doctorate from University of Pennsylvania School of Medicine.
Synagis® and FluMist® are registered trademarks of MedImmune, LLC, an AstraZeneca PLC company.
About 3-V Biosciences
3-V Biosciences, Inc. is privately-held biopharmaceutical company dedicated to discovering and developing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of shortcomings of traditional pathogen-directed approaches. The Company is located in Menlo Park, California and is backed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates.
For additional information on 3-V Biosciences, please visit www.3vbio.com.
Stephen R. Brady
Vice President, Corporate Development, Strategy & Operations
SOURCE 3-V Biosciences, Inc.